Primär solitäres malignes Schwannom des N. trigeminus. Fallbericht mit Literaturübersicht
Standard
Primär solitäres malignes Schwannom des N. trigeminus. Fallbericht mit Literaturübersicht. / Moeller, H C; Heiland, M; Vesper, M; Hellner, D; Schmelzle, R.
in: Mund Kiefer Gesichtschir, Jahrgang 3, Nr. 6, 01.11.1999, S. 331-4.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Primär solitäres malignes Schwannom des N. trigeminus. Fallbericht mit Literaturübersicht
AU - Moeller, H C
AU - Heiland, M
AU - Vesper, M
AU - Hellner, D
AU - Schmelzle, R
PY - 1999/11/1
Y1 - 1999/11/1
N2 - We present the case of a primary solitary malignant schwannoma of the trigeminal nerve. A total of 55 cases have been described in the literature; however, in these cases two tumors were affecting the supraorbital branch. This nerve-sheath tumor usually affects men in the fifth decade of life. The main clinical sign of malignant schwannomas of the head and neck is an indolent swelling. Hematogenic or lymphogenic metastasis has not been described. Because of the pleomorphism of the tumor cells immunohistochemical study is important. The treatment of choice is radical resection, possibly with adjuvant radio- or chemotherapy. The 5-year survival rate of malignant schwannoma of the trigeminal nerve is 41.7%.
AB - We present the case of a primary solitary malignant schwannoma of the trigeminal nerve. A total of 55 cases have been described in the literature; however, in these cases two tumors were affecting the supraorbital branch. This nerve-sheath tumor usually affects men in the fifth decade of life. The main clinical sign of malignant schwannomas of the head and neck is an indolent swelling. Hematogenic or lymphogenic metastasis has not been described. Because of the pleomorphism of the tumor cells immunohistochemical study is important. The treatment of choice is radical resection, possibly with adjuvant radio- or chemotherapy. The 5-year survival rate of malignant schwannoma of the trigeminal nerve is 41.7%.
KW - Aged
KW - Combined Modality Therapy
KW - Female
KW - Head and Neck Neoplasms
KW - Humans
KW - Immunohistochemistry
KW - Magnetic Resonance Imaging
KW - Male
KW - Neoplasms, Nerve Tissue
KW - Neurilemmoma
KW - Postoperative Care
KW - Survival Rate
KW - Treatment Outcome
KW - Trigeminal Nerve
M3 - SCORING: Zeitschriftenaufsatz
C2 - 10643286
VL - 3
SP - 331
EP - 334
IS - 6
ER -